Federal: Scope of Practice

This FDA guidance does not immediately expand your scope of practice or create new billing opportunities. You cannot yet bill insurance or patients for psychedelic-assisted therapy, nor does this guidance authorize therapists to administer psychedelics. However, the document establishes the regulatory framework that will determine whether psychedelic-assisted therapy eventually becomes a reimbursable clinical service within your scope. What matters now is monitoring which compounds complete FDA trials and what professional role requirements emerge. If psilocybin or MDMA-assisted therapy achieves FDA approval (expected 2024-2025 for MDMA), the guidance signals that the FDA will require specialized training, structured protocols, and integration into controlled clinical settings. Your practice should not assume these therapies will be immediately available to you or your patients—approval will likely restrict delivery to certified clinics initially, similar to the opioid antagonist naltrexone implant model. The guidance is a planning document for pharmaceutical sponsors and clinical trial sites, not a practice authorization for community mental health providers. If your practice is considering future involvement in psychedelic-assisted therapy, you'll need to track FDA approval timelines and watch for scope-of-practice legislation at the state level, which typically lags federal approval by 12-24 months.